Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB has announced a fully guaranteed rights issue of units, with CEO Petter Segelman Lindqvist discussing the background, terms, and future plans in an interview with Redeye. This move is part of Isofol’s strategy to advance its drug development efforts and strengthen its financial position, potentially impacting its market presence and offering new opportunities for stakeholders.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing a drug candidate, arfolitixorin, which aims to enhance the effectiveness of first-line standard treatments for various solid tumors, particularly in colorectal cancer. Isofol is conducting a phase Ib/II study to optimize the drug’s dosage regimen.
Average Trading Volume: 376,347
Current Market Cap: SEK262.6M
For detailed information about ISOFOL stock, go to TipRanks’ Stock Analysis page.